Latest Oncology News

Pirtobrutinib Delivers Strong Responses and Durable Benefit in Pretreated CLL/SLL in Final BRUIN Analysis

December 7th 2025

Caroline Seymour

Final data from the BRUIN trial show pirtobrutinib achieved an 81.6% ORR and durable outcomes with a favorable safety profile in previously treated CLL/SLL.

“Smart” Strategy of Up-front Targeted Therapy Reduces Need for Chemo in LBCL

December 7th 2025

Kristie L. Kahl

Treating with targeted therapy for the first 4 cycles showed potential curative intent without impacting patient response to subsequent chemotherapy.

INCA033989 With/Without Ruxolitinib Is Safe, Drives Spleen and Anemia Responses in CALR Exon 9–Mutated Myelofibrosis

December 7th 2025

Chris Ryan

INCA033989 given with or without ruxolitinib was well tolerated and yielded spleen and anemia responses in myelofibrosis with CALR exon 9 mutations

Revumenib Plus Decitabine/Cedazuridine and Venetoclax Proves Efficacious in Newly Diagnosed AML

December 7th 2025

Kristi Rosa

The SAVE regimen shows high response and MRD negativity rates in patients with AML, but myelosuppression and infectious complications remain key concerns.

Blinatumomab Plus Ponatinib Shows Survival Advantage Over Chemo/TKI Regimen in Ph+ ALL

December 7th 2025

Ariana Pelosci

Initial results from the phase 3 GIMEMA ALL2830 trial support the use of this chemotherapy-free approach as a new SOC for adult Ph-positive ALL.

Latest Oncology Videos

Dr Jen on the Efficacy of an All-Oral, Revumenib-Containing Regimen in AML

Cost-Effectiveness and Closing Perspectives in Early-Stage NSCLC

Dr Goulart on the Efficacy of Frontline Blinatumomab Plus Ponatinib in Ph+ B-ALL

Positioning CAR T Therapy in Marginal Zone Lymphoma: Efficacy, Safety, and Comparative Insights

43rd Annual Chemotherapy Foundation Symposium: The Show and After Show

Dr Scanlon on the Incidence, Management, and Physiologic Impact of IVC Tumor Thrombus in RCC

Dr Li on Progression Risk in Low-Grade NMIBC and the Emerging Role of AI-Based Pathology Assessment

Dr Desai on Future Research Directions in MPN and Other Hematologic Malignancies

Dr George on Early Insights and Future Directions for Water Vapor Thermal Therapy in Prostate Cancer

Dr Lyon on Logistical and Clinical Challenges Associated With Intravesical Therapy for NMIBC

Dr Jhaveri on the FDA Approval of Imlunestrant for ESR1+ Breast Cancer

Key Messages From the Breast Cancer ADC Data Set and Closing Remarks

Treatment Duration, Maintenance Concepts, and Development of New ADC Targets in Breast

Combination Approaches With ADCs and Emerging Clinical Strategies in Breast Cancer

Rechallenge Strategies, Practice Logistics, and Patient Communication Regarding ADCs in Breast Cancer

Selecting HER2 or TROP2 Directed ADCs in HER2 Low and Hormone Receptor Positive Breast Cancer

Supportive Care and Scheduling for Sacituzumab Govitecan in Clinical Practice in Breast Cancer

Clinical Impact of Datopotamab Deruxtecan in First Line Triple Negative Breast Cancer

CNS Recurrence and the Expanding Role of ADCs in Breast Cancer

Outcomes With Blinatumomab in Younger Adults With BCR:ABL1–negative B-ALL

Emerging Strategies for ALK+ NSCLC

Endometrial Cancer: Interpreting dMMR and Post-Adjuvant Activity from LEAP-001

Assessing Relapse: Clinical, Biological, and Patient-Centered Considerations

All Oncology News

Belzutifan Maintains High, Durable Responses in VHL Disease–Associated Neoplasms At 5 Years

December 5th 2025

Courtney Flaherty

At 48 months, the majority of patients with VHL disease–associated tumors remained in response following treatment with belzutifan.

Meta Analyses Show Suboptimal Efficacy With BCG in Metachronous NMIBC

December 5th 2025

Chris Ryan

Those with metachronous NMIBC experienced poorer outcomes with BCG vs those with primary NMIBC.

Previewing Top Myeloma Abstracts Set to Make Waves at ASH 2025

December 5th 2025

Chris Ryan

A look at the top multiple myeloma abstracts set to be presented at the 2025 ASH Annual Meeting.

All Eyes Are on Novel Combination Therapies and Molecular Targets in MPN at ASH 2025

December 5th 2025

Courtney Flaherty

Ahead of the 2025 ASH Annual Meeting, experts in myeloproliferative neoplasms share the most anticipated research being presented during the meeting.

Sylvester’s Researchers Lead Major Treatment Overhauls For Acute Myeloid Leukemia

December 5th 2025

Sylvester Comprehensive Cancer Center

Researchers at Sylvester Comprehensive Cancer Center lead the way in innovative AML treatments.

Inside the Most Anticipated CLL Abstracts: What to Expect From ASH 2025

December 5th 2025

Kyle Doherty

Ahead of the 2025 ASH Annual Meeting, OncLive spoke with experts in CLL care to preview the most anticipated meeting abstracts.

Adjuvant Pembrolizumab Delivers Long-Term Benefits in ccRCC at Increased Risk of Recurrence

December 5th 2025

Kristi Rosa

Adjuvant pembrolizumab delivers sustained clinical benefits across ccRCC subgroups with no new long-term safety signals.

Role of Age and Ph Status in Blinatumomab Selection in ALL

December 5th 2025

Jonathan Webster, MD

Jonathan Webster, MD, and Nikesh Shah, MD, discuss who age and Philadelphia chromosome status influence blinatumomab initiation in ALL.

Evolving First-Line Standards and the Foundation of Follicular Lymphoma Care

December 5th 2025

Amitkumar Mehta, MD

This segment outlines how clinicians today approach initial management, recognizing that improved survival and expanding treatment choices have dramatically changed the patient journey. As Mehta and Bailey note, frontline success does not eliminate the likelihood of relapse, making it essential to anticipate how early decisions may influence subsequent therapeutic sequencing.

Resistance Mechanisms and Molecular Testing in ALK Inhibitor–Treated NSCLC

December 5th 2025

Stephen Liu, MD

Panelists discuss mechanisms of acquired resistance to ALK inhibition and how molecular testing guides sequencing strategies.

Endometrial Cancer Today: Defining the Persistent Unmet Needs in Advanced and Recurrent Disease

December 5th 2025

Nicoletta Colombo, MD, PhD

Panelists discuss how advanced/recurrent endometrial cancer has remained a high unmet need due to years of minimal survival gains with carboplatin/paclitaxel until immunotherapy began shifting outcomes.

NDV-01 Elicits 92% CR Rate in High-Risk NMIBC

December 5th 2025

Caroline Seymour

Novel sustained-release NDV-01 achieved a 92% CR rate in high-risk patients with NMIBC with strong safety, supporting advancement to phase 3 studies.

Clinical Significance of ADC in Breast Cancer: Updates Presented at ESMO 2025

December 5th 2025

Paolo Tarantino, MD

Experts analyze groundbreaking antibody drug conjugate findings from ESMO 2025, highlighting their impact on breast cancer treatment strategies and patient care.

VISION Data Show Promise of Tepotinib in Treatment-Naive NSCLC Harboring MET Exon 14 Skipping Mutations: With Catherine Shu, MD

December 5th 2025

Catherine Shu, MD

Dr Shu discusses updated data from the VISION trial of tepotinib in patients with non–small cell lung cancer harboring MET exon 14 skipping mutations.

FDA Approves Liso-Cel for Relapsed/Refractory Marginal Zone Lymphoma

December 4th 2025

Jax DiEugenio

The FDA approved liso-cel for relapsed/refractory MZL after 2 prior lines of therapy.

See All News